Support Pullquote, upgrade to Pro!
(Or just tweet your Pullquote for free!)
With Pullquote Pro, you'll get to:
- share on Facebook
- schedule tweets
- tweet from multiple accounts
- edit quotes
- customize colors
- change fonts
- save and index quotes
- private quotes
Choose a plan: $5/month $50/year (includes free access to any new features)
Recent quotes:
Your Lab Tests - by Eric Topol - Ground Truths
You can see in the graph below that inter-individual vacation is far greater than intra-individual variation for each of the CBC metrics, and that long-term (15-year+) variation is similar to short-term at the individual level. On that note, these same researchers had previously shown that even after an acute event such as infection, trauma, or marked inflammation, the CBC setpoint values for that individual return to baseline. There are examples when that isn’t necessarily the case, as seen with the increase in hemoglobin and hematocrit in women after menopause (as presented in the Supplementary material) but overall the stability of the CBC metrics in any given individual over decades is notable. That was also shown to be th case across age, sex, race and ethnicity.
Continuous glucose monitoring to improve health in non-diabetics
For instance, in the Hall et al. study cited above, those with a glucotype associated with the largest fluctuations in blood glucose – roughly 24% of all normoglycemic participants tested – were found to spend roughly 15% of their time (over a 2-4 week test period) with glucose levels exceeding the threshold for prediabetes, demonstrating how even those considered metabolically healthy can have subclinical metabolic dysregulation that would likely be missed by a one-time blood glucose measurement.
Ultra-precision medicine | Nature Biotechnology
A Comment in this issue describes n-Lorem, an ambitious not-for-profit initiative with a mission to discover individualized experimental antisense oligonucleotide (ASO) treatments for patients with ultra-rare conditions arising from a single, often de novo, mutation (for example, an indel, repeat or single point mutation). Since its founding last year, n-Lorem has built a network of public–private partnerships with Ionis Pharmaceuticals, Biogen, Ultragenyx, Charles River Laboratories, Covance, the Korea Institute of Toxicology and the US National Institutes of Health’s Undiagnosed Disease Network to discover and develop individualized ASO drugs collaboratively with clinical investigators in academic medical centers.
